Primary source: Open Government Licence v3.0
A partnership was established to create a health innovation sandbox which will allow innovative technologies to be deployed and tested in NHS settings, generating evidence on their effectiveness and safety.
This partnership aims to address the challenge of proving new technologies work effectively in real healthcare environments, facilitating earlier diagnosis and personalized care for patients while enhancing the safety assessment processes within the NHS.
The program will implement collaborative processes for the evaluation of technologies, enhancing real-world evidence integration into signal management and impacting regulatory compliance workflows.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
The program will implement collaborative processes for the evaluation of technologies, enhancing real-world evidence integration into signal management and impacting regulatory compliance workflows.
The Medicines and Healthcare products Regulatory Agency (MHRA) and Manchester University NHS Foundation Trust (MFT) have launched a new partnership to create a health innovation sandbox aimed at testing innovative technologies within the NHS. This initiative seeks to rapidly evaluate healthcare solutions that can improve patient care, safety, and access to new technologies, particularly focusing on AI-enabled medical devices.
What changed: A partnership was established to create a health innovation sandbox which will allow innovative technologies to be deployed and tested in NHS settings, generating evidence on their effectiveness and safety.
Why it matters: This partnership aims to address the challenge of proving new technologies work effectively in real healthcare environments, facilitating earlier diagnosis and personalized care for patients while enhancing the safety assessment processes within the NHS.
Practical implication: The program will implement collaborative processes for the evaluation of technologies, enhancing real-world evidence integration into signal management and impacting regulatory compliance workflows.
Published from the regulator source ingestion pipeline after PV impact triage.
Ensure that all labeling and safety information reflects the updated product name 'Prasugrel Viatris' instead of 'Prasugrel Mylan'.
Operational support will now be increased for disease surveillance, health worker assistance, and community outreach based on the new funding and response framework.
Enhanced monitoring for products with hidden drug ingredients is required, leading to increased need for rapid reporting and investigation of adverse events associated with similar products.
Applicants must adhere to new timelines: submit a rapporteurs' allocation request 9 months prior to the intended MAA submission date, and submit their Letter of Intent at least 2 months before the MAA submission.
